🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "significant breakthrough" in the fight against increasingly resistant strains of the infection, according to health experts.

A Worldwide Challenge

Cases of gonorrhoea are increasing globally, with figures suggesting more than 82 million infections each year. Especially elevated rates are observed in the African continent and nations within the WHO's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune step in the face of rising global incidence, escalating drug resistance and the highly restricted available drugs presently on offer.”

Health officials are particularly alarmed about the rise in antibiotic-resistant strains. The global health body has classified it as a "high-priority threat". A tracking program revealed that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Drugs Receive Approval

Zoliflodacin, alternatively called a brand name, was cleared by the US FDA in December for combating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Scientists believe that specific application of this new drug will help slow the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in close succession. This medication, which is also used to treat urinary tract infections, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin was the result of a new, not-for-profit approach for drug creation. The non-profit organisation GARDP partnered with the drug firm Innoviva to develop it.

“This approval signifies a significant shift in the treatment of superbug gonorrhoea, which up to this point has been outpacing antibiotic development.”

Research Study Outcomes and Global Access

According to data published in a prominent scientific publication, the new drug eradicated the vast majority of cases of the STI. This establishes an equal footing with the existing first-line therapy, which involves an injection and a pill. The study included over 900 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, the non-profit has the ability to register and commercialise the drug in a wide range of developing nations.

Clinicians directly involved have expressed optimism. The availability of a single-dose, oral treatment such as this is seen as a "revolutionary step" for managing the epidemic. This is considered essential to lessen the impact of the illness for individuals and to prevent the spread of highly drug-resistant gonorrhoea globally.